Evaluation of the Immune Restoration Potential Of Lenalidomide
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is phase 2 study of the immunomodulatory drug, lenalidomide, to evaluate potential
beneficial effects on the immune system of patients with chronic lymphocytic leukemia (CLL)
and CLL-associated immunodeficiency. 17 patients will be enrolled with CLL, small lymphocytic
lymphoma (SLL), or monoclonal B-cell lymphocytosis (MBL), and measurable immune compromise,
but not an iwCLL indication for CLL therapy (ie non-progressive disease).